Q1 Earnings Forecast for NRIX Issued By Leerink Partnrs

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Nurix Therapeutics in a report issued on Monday, March 17th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings of ($0.89) per share for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q2 2025 earnings at ($0.93) EPS.

NRIX has been the subject of a number of other reports. BMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. JPMorgan Chase & Co. lowered their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. BTIG Research began coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective on the stock. Morgan Stanley lifted their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, February 3rd. Finally, Needham & Company LLC dropped their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.88.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $13.66 on Wednesday. Nurix Therapeutics has a 1 year low of $11.90 and a 1 year high of $29.56. The stock has a 50 day simple moving average of $17.33 and a two-hundred day simple moving average of $20.98. The firm has a market cap of $1.04 billion, a P/E ratio of -4.73 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%.

Institutional Trading of Nurix Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Amalgamated Bank boosted its stake in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after acquiring an additional 511 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of Nurix Therapeutics during the third quarter valued at approximately $484,000. Quest Partners LLC boosted its position in shares of Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock worth $168,000 after purchasing an additional 1,312 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Nurix Therapeutics in the 3rd quarter worth approximately $425,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Nurix Therapeutics during the 3rd quarter valued at approximately $530,000.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $488,660.76. This represents a 14.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,326 shares of company stock valued at $213,449. Company insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.